Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other 1Gynecologic 1

Conditions

Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 111Cyclophosphamide 109pembrolizumab 78Radiotherapy 77Nivolumab 74Cisplatin 69fludarabine 68Carboplatin 61Biopsy 53Paclitaxel 46Standard of Care 45Radiosurgery 41Gemcitabine 41Dexamethasone 40Doxorubicin 38Rituximab 37venetoclax 36Radiation 36Blood Specimen Collection 36fludarabine phosphate 35Cytarabine 35Surveys and Questionnaires 34Bevacizumab 32Capecitabine 31Radiotherapy, Intensity-Modulated 30Ipilimumab 28Etoposide 28durvalumab 27Temozolomide 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Bupropion × 30 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡